Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Northern California

Activity Overview

The management of advanced melanoma continues to evolve rapidly, with oncolytic immunotherapies emerging as pivotal, tailored treatment options. Despite these advancements, challenges with integrating these therapies into multidisciplinary clinical practice remain at the forefront.

This symposium brings together an expert in melanoma management with a local community oncologist to discuss the importance of multidisciplinary collaborative care. It features real-world, practical, case-based discussions to optimize treatment sequencing and selection for patients with advanced melanoma. A focus on understanding resistance to first-line therapies and exploring advanced therapeutic strategies, such as oncolytic viruses and combination immunotherapies, will help practicing clinicians navigate the complexities of advanced melanoma treatment. The interactive case-based discussions will provide participants with actionable strategies for lesion prioritization and evaluation, procedural workflow integration, and insight into evidence-based decision-making to help inform treatment selection. By incorporating the latest clinical trial data, the program will offer insights into the efficacy, safety, and real-world application of these innovative therapies to advance personalized care and optimize outcomes for patients with advanced melanoma.

This educational activity is an archive of the live presentation held on November 3, 2026.

Target Audience

This educational program is directed toward community-based medical oncologists, interventional radiologists, surgeons, nurse practitioners, nurses, pharmacists, and other health care professionals involved in the treatment of advanced melanoma.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate clinical and safety data for second-line therapies in melanoma, including oncolytic viruses, tumor-infiltrating lymphocytes, and combination immunotherapies, in patients with progression on PD-1 inhibitors
• Describe the mechanistic rationale, administration techniques, and clinical benefits of oncolytic viruses in advanced melanoma
• Apply best practices for multidisciplinary care of patients receiving intratumoral oncolytic immunotherapies, including coordination between medical oncologists, interventional radiologists, nurse practitioners, nurses, pharmacists, and surgical oncologists

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.

This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.

The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.

This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.